Innovative Genetic Approaches to Enhance Liver Repopulation and Reduce Cancer Risk and Progression

增强肝脏再生并降低癌症风险和进展的创新遗传学方法

• 批准号: 10434813
• 负责人: KLAUS H KAESTNER
• 金额: $ 53.34万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-07-15 至 2025-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10434813
• 关键词: Acute; Acute Liver Failure; Attenuated; BAY 54-9085; Biological Models; Clinical Treatment; Complementary DNA; DNA; Data; Development; Disease; Early Diagnosis; Evaluation; FDA approved; Genes; Genetic; Genetic Screening; Genotype; Grant; Growth; Health; Hepatic; Hepatocyte; High-Throughput Nucleotide Sequencing; Human; Individual; Injury; Investigation; Knockout Mice; Length; Libraries; Liver; Liver Extract; Liver Regeneration; Liver diseases; Malignant Neoplasms; Malignant neoplasm of liver; Maps; MicroRNAs; Modeling; Mus; Mutation; Natural regeneration; Neoplasms; Oncogenes; Oncogenic; Partial Hepatectomy; Pathway interactions; Patients; Pharmacotherapy; Phenotype; Plasmids; Porifera; Prevention; Primary carcinoma of the liver cells; Process; Prognosis; Recovery; Resistance; Risk; Role; Survival Rate; TP53 gene; Technology; Testing; The Cancer Genome Atlas; Toxic Hepatitis; Transforming Growth Factor alpha; Tumor Burden; Tyrosine Kinase Inhibitor; United States; Xenograft Model; Xenograft procedure; acetaminophen overdose; acute liver injury; base; cancer prevention; cancer risk; chronic liver disease; chronic liver injury; effective therapy; genetic approach; genetic makeup; hepatocellular carcinoma cell line; improved; in vivo; inhibitor; innovation; liver cancer model; liver cell proliferation; liver injury; mimetics; mouse model; nanoparticle; new combination therapies; novel; novel therapeutics; overexpression; prevent; response; screening; small hairpin RNA; therapeutic target; tumor; tumor growth; tumor initiation; tumor progression; tumorigenesis

A better understanding of the liver’s response to toxic injury, which includes hepatocyte proliferation, and – unfortunately – an increased risk for hepatocellular carcinoma (HCC), is a prerequisite for the development of novel clinical treatments for chronic liver disease and improved cancer prevention. Existing drug therapies for HCC such as sorafenib extend patient survival by only three months. We recently developed a massively parallel in vivo screening platform to test the impact of genetic factors such as full-length cDNAs or miRNAs on liver repopulation and tumorigenesis. We have used this screening technology to build a map of all miRNAs active in liver regeneration. Here, we propose to exploit this innovative paradigm to conduct a comprehensive evaluation of the effects of the 135 most abundant but evolutionarily conserved hepatic miRNAs on the processes of recovery from toxic liver injury and HCC tumorigenesis. In Specific Aim 1, we will determine the combined benefits of three miRNAs identified in our prior screen on liver repopulation following toxic injuries, as a step toward using miRNA-mimetic drug therapies for liver diseases. This will be accomplished through delivery of miRNA-encoding plasmids or nanoparticles singly and in all combination. In Specific Aim 2, we will determine the impact of hepatic miRNAs and miRNA combinations on HCC tumor development in vivo. To this end, we have developed two models of rapid HCC development in mice, in which we will screen our library of 135 ‘tough decoys’ (“TuD’s”), or inhibitors of miRNA action, on tumor formation. We will quantify the abundance of all TuD’s using high throughput sequencing in the tumor-loaded liver compared to the input library. TuD’s enriched in after tumor formation target miRNAs that normally limit tumor growth, and those found less abundant target miRNAs that promote tumorigenesis. We will then test the combinations of the most potent miRNA effectors on tumor formation following systemic delivery. In Specific Aim 3 we will perform a conditional screen of miRNAs that impact Sorafenib resistance to identify novel combination treatments for the prevention or treatment of HCC. Together, our powerful genetic screens promise to identify miRNA effectors that can be employed for the treatment of acute liver injury and, in combination with Sorafenib, as a more effective treatment to prevent HCC initiation and progression.

更好地了解肝脏对毒性损伤的反应，包括肝细胞增殖， 不幸的是，患肝细胞癌(HCC)的风险增加是 开发慢性肝病的新临床治疗方法和改进癌症预防。现有 索拉非尼等治疗肝癌的药物仅将患者的生存期延长了三个月。我们最近开发了 一个大规模平行的体内筛选平台，用于测试遗传因素的影响，如全长cDNA或 MiRNAs对肝脏再繁殖和肿瘤发生的影响。我们已经使用这项筛选技术建立了一张所有 参与肝脏再生的miRNAs。在这里，我们建议利用这一创新范式来进行 135个最丰富但进化保守的肝脏的影响的综合评估 MiRNAs在中毒性肝损伤恢复和肝细胞癌发生过程中的作用在具体目标1中，我们将 确定在我们之前的筛查中确定的三种miRNAs对以下肝脏再繁殖的综合益处 毒性损伤，作为使用miRNA模拟药物疗法治疗肝病的一步。这将是 通过单独和所有组合递送miRNA编码的质粒或纳米颗粒来完成。在……里面 特定目标2，我们将确定肝脏miRNAs和miRNA组合对肝癌肿瘤的影响 体内发育。为此，我们开发了两种快速发展的小鼠肝癌模型，其中 我们将筛选我们的135个“坚韧诱饵”(“TUD‘s”)库，或miRNA作用的抑制物，用于肿瘤形成。 我们将使用高通量测序技术对荷瘤肝脏中所有TUD的丰度进行量化 与输入库相比。TUD在肿瘤形成后富含通常限制肿瘤的miRNAs 生长，以及那些发现不太丰富的促进肿瘤发生的靶miRNA。然后我们将测试 全身给药后对肿瘤形成影响最强的miRNA效应器的组合。具体而言 目的3我们将对影响索拉非尼耐药性的miRNAs进行有条件的筛选，以确定新的 预防或治疗肝细胞癌的联合治疗。一起，我们强大的基因筛查 承诺确定可用于治疗急性肝损伤的miRNA效应器，并在 联合索拉非尼是预防肝细胞癌发生和发展的更有效的治疗方法。